V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320004010 | 320005118 | 1.62 | null | Palliative (P) | 2013-07-10 | 2013-07-30 | CISPLATIN + GEMCITABINE | N | N | 320012978 | ICON8B TRIAL |
| 320004011 | 320002460 | 1.6 | 66 | Palliative (P) | 2014-10-21 | 2014-10-21 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | N | 320012990 | CAPECITABINE + CARBOPLATIN |
| 320004012 | 320002460 | null | 72.7 | null | 2014-02-19 | 2014-02-23 | CISPLATIN + GEMCITABINE | N | null | 320012990 | CAPECITABINE + CISPLATIN |
| 320004013 | 320002461 | 1.66 | 145 | Palliative (P) | 2015-04-14 | 2015-04-21 | Trial Unspecified | 02 | N | 320013005 | ICON8B TRIAL |
| 320004014 | 320002461 | 1.49 | 52.2 | Palliative (P) | 2018-08-07 | 2018-08-08 | Bevacizumab 15mg/kg | N | N | 320013005 | LANREOTIDE |
| 320004015 | 320002461 | 1.6 | 70.2 | Adjuvant (A) | 2017-01-21 | 2017-01-21 | Oxaliplatin + Modified de Gramont | Y | N | 320013005 | IMATINIB |
| 320004016 | 320002461 | 1.6 | 54.8 | Palliative (P) | 2017-05-11 | 2017-05-16 | CETUXIMAB + CISPLATIN + FU | N | Y | 320013005 | CETUXIMAB + RT |
| 320004017 | 320002461 | 1.73 | 68.6 | Neo-adjuvant (N) | 2017-04-30 | 2017-04-30 | Oxaliplatin + Modified de Gramont | N | N | 320013005 | BEVACIZUMAB |
| 320004018 | 320002462 | 1.7 | null | Palliative (P) | 2015-07-17 | 2015-07-18 | CISPLATIN + FLUOROURACIL + RT | null | null | 320013335 | CISPLATIN + GEMCITABINE |
| 320004019 | 320002463 | null | 79 | Palliative (P) | null | 2015-07-20 | CETUXIMAB | N | N | 320013406 | DOXORUBICIN |
| 320004020 | 320002464 | 1.65 | null | null | 2017-02-13 | 2017-02-28 | CETUXIMAB | N | null | 320013419 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004021 | 320002464 | 1.67 | 78.7 | Not known (9) | 2019-03-11 | 2019-03-11 | ECX | 2 | N | 320013419 | CAPECITABINE + CISPLATIN |
| 320004022 | 320002464 | 1.59 | 40 | Curative (C) | 2015-06-19 | 2015-06-29 | CARBOPLATIN + RT | N | Y | 320013419 | DOCETAXEL |
| 320004023 | 320002465 | 1.57 | 0 | Palliative (P) | 2017-02-11 | 2017-03-01 | Imatinib 400mg | Y | N | 320013488 | CAP |
| 320004024 | 320005122 | null | 151 | Not known (9) | 2017-08-15 | 2017-08-20 | ECarboX | 2 | N | 320013501 | IPILIMUMAB |
| 320004025 | 320002466 | 1.68 | null | Palliative (P) | 2016-12-05 | 2016-12-12 | Cisplatin + Etoposide (3 day) | N | N | 320013669 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004026 | 320002467 | 1.62 | 80 | null | 2016-11-23 | 2016-11-27 | CETUXIMAB + RT | N | null | 320013719 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 320004027 | 320002467 | 1.58 | 42.5 | Palliative (P) | 2016-02-10 | 2016-02-10 | Ipilimumab | 2 | N | 320013719 | CAP |
| 320004028 | 320002468 | 1.79 | 87 | Curative (C) | 2014-05-27 | 2014-05-27 | CARBOPLATIN + RT | N | N | 320013788 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004029 | 320002468 | 1.82 | -1 | null | 2015-12-30 | 2015-12-30 | CAPECITABINE + RT | N | null | 320013788 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004030 | 320002469 | 1.8 | 0 | Palliative (P) | 2018-05-12 | 2018-05-30 | Cisplatin + Pemetrexed | N | N | 320013895 | CARBOPLATIN + ETOPOSIDE |
| 320004031 | 320002470 | null | 90.35 | Not known (9) | 2016-10-06 | 2016-10-24 | Carbo F | 02 | N | 320014024 | CARBOPLATIN + RT |
| 320004032 | 320002471 | 1.51 | 136 | null | 2017-04-03 | 2017-04-22 | Trial Unspecified | N | N | 320014043 | ECX |
| 320004033 | 320002472 | 1.58 | 95.3 | Palliative (P) | 2019-02-22 | 2019-03-07 | LANREOTIDE | N | N | 320014141 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320004034 | 320002473 | 1.51 | 48 | Palliative (P) | 2018-03-20 | 2018-04-11 | ECX | N | N | 320014151 | RCEOP |
| 320004035 | 320002474 | 0 | 42.5 | Neo-adjuvant (N) | 2015-01-23 | 2015-04-24 | CHOP R - 21 days | N | N | 320014204 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 320004036 | 320002475 | 1.7 | 98.3 | Adjuvant (A) | 2015-10-02 | 2015-10-03 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | 320014226 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 320004037 | 320002475 | null | 58.8 | Neo-adjuvant (N) | 2016-06-04 | 2016-06-04 | TIP | N | N | 320014226 | CETUXIMAB + RT |
| 320004038 | 320002476 | 1.59 | 79 | Palliative (P) | 2018-05-23 | 2018-05-29 | Doxorubicin + Ifosfamide | 02 | N | 320014425 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004039 | 320002477 | 1.67 | 79.4 | Curative (C) | null | 2016-07-19 | TIP | N | N | 320014489 | CARBOPLATIN + RT |
| 320004040 | 320005126 | 1.63 | 92.5 | Palliative (P) | 2017-12-11 | 2017-12-13 | VIDE | N | null | 320014492 | TRIAL |
| 320004041 | 320002478 | 1.83 | null | Palliative (P) | 2017-10-31 | 2017-11-16 | Carboplatin+Fluorouracil 4 or 5 day | Y | null | 320014558 | OXALIPLATIN + MDG |
| 320004042 | 320002479 | 1.57 | 45.7 | Disease modification (D) | 2013-07-10 | 2013-07-21 | Bevacizumab+Carbo+Gemcitabine | N | N | 320014660 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320004043 | 320002480 | 1.6 | 43 | Curative (C) | 2019-03-17 | 2019-03-24 | CETUXIMAB | 02 | null | 320014711 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004044 | 320002481 | 1.77 | 83 | Palliative (P) | 2016-04-14 | 2017-05-04 | Trial Unspecified | 02 | N | 320014931 | IMATINIB |
| 320004045 | 320002482 | 1.59 | 78.5 | Curative (C) | 2016-07-25 | 2016-08-13 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | Y | 320015228 | CAPECITABINE + OXALIPLATIN |
| 320004046 | 320002483 | 1.44 | 50.5 | Palliative (P) | 2014-01-16 | 2014-02-22 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 2 | Y | 320015291 | ECF |
| 320004047 | 320002483 | null | 81.5 | Disease modification (D) | 2017-09-19 | 2017-09-23 | BCG Intravesical | N | N | 320015291 | CETUXIMAB |
| 320004048 | 320002484 | 1.9 | 64.8 | null | 2016-11-20 | 2017-01-02 | Cisplatin + Gemcitabine (D 1 & 8) | N | Y | 320015394 | DOCETAXEL |
| 320004049 | 320002485 | null | 81.9 | Palliative (P) | 2015-03-15 | 2015-01-18 | CETUXIMAB | null | null | 320015543 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320004050 | 320002485 | 1.72 | 65.1 | Palliative (P) | 2017-10-05 | 2017-10-11 | Cisplatin + Gemcitabine (D 1 & 8) | 01 | N | 320015543 | TEMOZOLOMIDE |
| 320004051 | 320002486 | 1.65 | 29.1 | Adjuvant (A) | 2018-07-04 | 2018-07-25 | Carboplatin + Docetaxel | 02 | N | 320015631 | CAPECITABINE + OXALIPLATIN |
| 320004052 | 320002486 | null | null | Curative (C) | 2017-05-13 | 2017-06-02 | Cisplatin + Gemcitabine (D 1 & 8) | N | Y | 320015631 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004053 | 320002486 | 1.7 | 68.3 | Palliative (P) | 2017-07-03 | 2017-07-10 | CETUXIMAB + RT | N | null | 320015631 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004054 | 320002487 | 1.63 | null | Palliative (P) | 2015-01-15 | 2015-01-17 | Docetaxel 75mg/m2 (21 day) | Y | null | 320015814 | CARBOPLATIN + LIPOSOMAL DOX |
| 320004055 | 320002488 | 1.71 | 93 | Neo-adjuvant (N) | 2016-04-02 | 2016-04-02 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320015886 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320004056 | 320002489 | 1.58 | 76.8 | Palliative (P) | 2017-03-01 | 2017-03-03 | Bevacizumab + CARBOPLATIN + GEMCITABINE | 02 | N | 320015925 | DOXORUBICIN |
| 320004057 | 320005130 | 1.66 | 92.2 | Neo-adjuvant (N) | 2015-11-09 | 2015-11-23 | Cisplatin + Pemetrexed | 02 | N | 320015999 | BCG |
| 320004058 | 320005130 | 1.86 | 49.6 | Adjuvant (A) | 2017-05-26 | 2017-05-31 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320015999 | CISPLATIN + GEMCITABINE |
| 320004059 | 320002490 | 1.7 | 82 | Adjuvant (A) | 2017-01-10 | 2017-01-11 | Temozolomide + RT | 2 | N | 320016064 | CETUXIMAB |